BTIG Reiterates Buy on Humacyte, Maintains $3 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.3%

Neg 0% Neu 89.3% Pos 0%

BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $3 price target.

Comments

No comments yet. Be the first!